[Media Releases] Antibiotics of LegoChem selected for 'Pharm Navi' project (Health Korea News, 17 Oct 2014)
Title: Antibiotics of LegoChem selected for 'Pharm Navi' project Publication: Health Korea News / Sun-Ho Lee Date: 17 Oct 2014 URL: link to website (contents in Korean)
· Ministry of Food and Drug Safety in Korea selected LegoChem Biosciences' Oxazolidinone antibiotics project (LCB01-0371) as the second 'Pharm Navi' proejct for rapid commercialization of new medicines developed in domestic and supporting global expansion. · LegoChem’s LCB01-0371 project for oral administration is now completing Phase I, and the intravenous administration is soon entering the clinical stage.
About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |